Palazestrant Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Palazestrant comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Breast Neoplasms. Most recent publication: OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy., Future Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.
    Pistilli B, Bellet Ezquerra M, Del Mastro L, et al. · Future Oncol · 2026
    PubMed: PMID 41461598 · NCT06016738 (OPERA-01) · Breast Neoplasms

Publications by year

2026–2026: 1 publications.

2026
1

Publications by indication

Breast Neoplasms (1)

  • OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.
    Future Oncol · 2026 · PMID 41461598 · NCT06016738

Publications by journal

  • Future Oncol1 paper

All Palazestrant publications (1)

2026 (1 paper)

  1. OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.
    Pistilli B, Bellet Ezquerra M, Del Mastro L, et al. · Future Oncol · 2026 · Derived
    PubMed: PMID 41461598 · NCT06016738 (OPERA-01) · Breast Neoplasms

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Thu, 07 May 2026 20:18:16 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).
Palazestrant Evidence: 1 Peer-Reviewed Studies and Phase-3 Results | Hipa.ai